If you're an investor in biotech, you know the drill: a tiny company with a promising drug can either make you a fortune or break your heart. Today, Agenus (AGEN) is delivering the former.
The clinical-stage biotech reported updated three-year data from a Phase 1b trial of its botensilimab plus balstilimab combination in patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases. And the numbers are turning heads.
But that's not all. Agenus also announced a private placement that could bring in up to $340 million, led by some serious institutional names. The stock shot up more than 111% on Monday, bucking a weaker broader market. Let's break down what's happening.
Three-Year Data That Speaks Volumes
The latest results cover 123 heavily pretreated patients — people who have run out of standard options. With extended follow-up, the combination produced a median overall survival of 21.2 months. For context, later-line treatments in this population have historically delivered a median overall survival of roughly 10 to 14 months. That's a big jump.
The 24-month and 36-month overall survival rates reached 41% and 33%, respectively. Agenus says the survival curve plateaus beyond two years, and many patients remain alive without needing further systemic anticancer therapy. That durability is the kind of thing that gets oncologists excited.
The dataset included 26 confirmed responses: three complete responses and 23 partial responses, translating to a confirmed objective response rate of 21%. Median duration of response wasn't reached, with responses lasting from 1.9 months to at least 37.4 months. Disease control was achieved in 69% of patients at six weeks, and tumor regression was observed in more than 40% of participants.
These are the kind of numbers that make you sit up and pay attention.
A $340 Million Vote of Confidence
Alongside the clinical update, Agenus announced a private placement expected to provide approximately $85 million in upfront gross proceeds and up to an additional $255 million if accompanying warrants are fully exercised. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals (LGND).
The company said the proceeds will primarily support development of botensilimab plus balstilimab as a neoadjuvant treatment for microsatellite-stable colon cancer, including its planned registrational Phase 3 ROBBIN trial. Assuming full warrant exercise, Agenus expects the financing to fund completion of the study and provide operating runway through the end of 2031.
That's a long runway for a biotech — and a sign that serious investors believe in the science.
Focus Turns to ROBBIN Phase 3 Trial
Agenus is shifting its strategy. The company plans to discontinue financial support for its ongoing BATTMAN Phase 3 study in late-line metastatic microsatellite-stable colorectal cancer, while continuing to meet obligations for patients currently receiving treatment. The focus is now on the ROBBIN trial.
ROBBIN will enroll 850 patients with previously untreated high-risk Stage II and Stage III microsatellite-stable colon cancer. The trial will compare neoadjuvant botensilimab plus balstilimab followed by standard of care against standard of care alone. The primary endpoint is event-free survival.
The timeline is ambitious: first patient dosing in the first quarter of 2027, interim pathologic response data in the second half of 2027, an interim event-free survival analysis in the second half of 2029, and final analysis in the second half of 2030.
If the data holds up, this could be a game-changer for earlier-stage colon cancer treatment.
Stock Performance and Technical Analysis
Agenus stock surged more than 111% on Monday, while the Nasdaq fell 1.14% and the S&P 500 slipped 0.37%. At about $7.08, the stock was trading roughly 111% above its 20-day simple moving average of $3.36 and nearly 94% above its 200-day simple moving average of $3.65. It was also testing its 52-week high near $7.34.
The relative strength index stood at 85.67, placing the stock in overbought territory. A high RSI often signals strong buying momentum, but it can also indicate an increased risk of volatility or a short-term pullback. The longer-term chart still shows signs of recovery: the 20-day moving average remains below the 50-day moving average, and the stock is still working its way back from a bearish death cross that formed in December 2025. Even so, trading well above all major moving averages points to a strong near-term uptrend. The next key support level sits around $5.50, where buyers previously stepped in.
For now, Agenus is riding a wave of good news. Whether it can sustain that momentum depends on execution — and on whether the ROBBIN trial delivers the same kind of results we've seen so far.
